NASDAQ · ALMS
Alumis Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ALMS: Nov 12, 2026
Alumis Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.73. The reported EPS for the same quarter last year was $-1.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.73 | $-0.62 | $-0.80 | 5 |
| Dec 2026 | $-0.70 | $-0.64 | $-0.78 | 5 |
| Mar 2027 | $-0.73 | $-0.65 | $-0.79 | 3 |
| Jun 2027 | $-0.72 | $-0.66 | $-0.76 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · Fintel · MarketBeat- RTTNews · Oct 9, 9:05 AM EDTAlumis Shares New Phase 3 Psoriasis Data For Envudeucitinib; Stock Up(RTTNews) – Alumis Inc. (ALMS) announced new Phase 3 data showing that investigational envudeucitinib rapidly and durably improved scalp psoriasis, itching and quality of life in patients with moderate-to-severe plaque psoriasis. The findings from the ONWARD1, ONWARD2 and ONWARD3
- RTTNews · Oct 9, 7:58 AM EDTAlumis Reports Positive Phase 3 Data With Envudeucitinib(RTTNews) – Alumis (ALMS) announced envudeucitinib data from the ONWARD Phase 3 clinical program—ONWARD1, ONWARD2, and the long-term extension ONWARD3. The company said the results reinforced the potential of envudeucitinib to become a leading oral therapy for patients with moder
- BNK Invest · Sep 10, 10:44 AM EDTThursday 9/10 Insider Buying Report: ALMS, PRTSAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. On Tuesday, Alumis', Srinivas Akkaraju, made a $10.73M buy of ALMS, purchasing 986,
- Fintel · Sep 2, 4:23 PM EDTHC Wainwright & Co. Upgrades Alumis (ALMS)Fintel reports that on September 2, 2026, HC Wainwright & Co. upgraded their outlook for Alumis (NASDAQGS:ALMS) from Neutral to Buy. Analyst Price Forecast Suggests 334.42% Upside
- MarketBeat · Sep 1, 11:02 AM EDTAlumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise3 Biopharmaceutical Stocks Bucking the Sell-OffAlumis (NASDAQ:ALMS) said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specifie
- RTTNews · Sep 1, 9:20 AM EDTAlumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges(RTTNews) – Alumis Inc. (ALMS), announced topline results from its Phase 2b LUMUS trial of Envudeucitinib in moderate-to-severe systemic lupus erythematosus (SLE).
- BNK Invest · Aug 24, 3:24 PM EDTNoteworthy Monday Option Activity: DMC, RYAM, ALMSLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Del Monte Corp (Symbol: DMC), where a total volume of 2,409 contracts has been traded thus far today, a contract volume which is representative of approximately
- Zacks · Aug 11, 9:44 AM EDT4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
- RTTNews · Aug 11, 4:05 AM EDTAlumis: Envudeucitinib Delivered Highest PASI 100 Skin Clearance In Plaque Psoriasis(RTTNews) – Alumis Inc. (ALMS) announced long-term extension data from its ONWARD3 study showing that Envudeucitinib achieved the highest reported PASI 100 skin clearance rates among oral therapies for plaque psoriasis.
- Zacks · Aug 6, 7:10 PM EDTProthena (PRTA) Reports Q2 Loss, Misses Revenue EstimatesProthena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 14, 10:02 PM EDTTop Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch(RTTNews) – Among Friday's notable biotech movers were TherapeuticsMD, which is evaluating a strategic review process; Sensei Biotherapeutics, supported by optimism surrounding a key clinical catalyst expected in the second half of 2026; and Alumis, which is advancing its lead th
- The Motley Fool · May 24, 10:33 AM EDTThis Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last QuarterDeep Track Capital bought 6,772,595 shares of Alumis last quarter; the estimated transaction value was $169.31 million (based on average prices).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Alumis Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.